ERBB2 and breast cancer: Moreover, findings from the PALOMA-2 study revealed that PD-L1 expression is an insufficient biomarker for detecting immune activation in HR+ HER2-negative breast cancer, showing the urgent need for more reliable indicators to assess immune dynamics in this specific subtype [36].